Nemocnice Ceske Budejovice a.s.
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
The Cardiology Department at Nemocnice Ceske Budejovice a.s. conducts a series of trials aimed at improving outcomes for patients with heart‑related conditions, including the prevention of stroke and heart attack recurrence.
- Acute Coronary Syndrome
- Acute myocardial infarction (AMI)
- Atrial Fibrillation
- Atherosclerotic cardiovascular disease with elevated lipoprotein(a)
- Prevention of ischemic stroke after non‑cardioembolic stroke or high‑risk TIA
- Prevention of stroke or systemic embolism in atrial fibrillation
Ongoing studies evaluate the safety and effectiveness of new oral inhibitors such as milvexian and asundexian, compare them with standard anticoagulants, and test a rapid‑action agent, selatogrel, for self‑administration during suspected heart attacks. A lipid‑targeting therapy, olpasiran, is also being examined for its impact on coronary heart disease events.
Digestive System Disease Research
Researchers in the gastroenterology‑focused unit of Nemocnice Ceske Budejovice a.s. are testing innovative treatments for inflammatory bowel disorders, seeking better maintenance options and long‑term safety for patients.
- Crohn's Disease
- Ulcerative Colitis
The trials include a maintenance and long‑term extension study of the JAK inhibitor upadacitinib and an evaluation of the investigational compound JNJ‑77242113 for inducing clinical response in ulcerative colitis. The primary goal is to improve disease control while minimizing adverse effects.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Merck Sharp & Dohme LLC3active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International10trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Ceske Budejovice a.s.
lock Showing 1 of 37 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis | Janssen Cilag International | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 6 | Unknown | 2018-07-26 | 2024-11-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.